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ChloramphenicolComplex I (CI) of the oxidative phosphorylation system is assembled from 45 subunits encoded by both
the mitochondrial and nuclear DNA. Defective mitochondrial translation is a major cause of mitochondrial
disorders and proper understanding of its mechanisms and consequences is fundamental to rational treat-
ment design. Here, we used a live cell approach to assess its consequences on CI assembly. The approach con-
sisted of ﬂuorescence recovery after photobleaching (FRAP) imaging of the effect of mitochondrial translation
inhibition by chloramphenicol (CAP) on the dynamics of AcGFP1-tagged CI subunits NDUFV1, NDUFS3,
NDUFA2 and NDUFB6 and assembly factor NDUFAF4. CAP increased the mobile fraction of the subunits,
but not NDUFAF4, and decreased the amount of CI, demonstrating that CI is relatively immobile and does
not associate with NDUFAF4. CAP increased the recovery kinetics of NDUFV1-AcGFP1 to the same value as
obtained with AcGFP1 alone, indicative of the removal of unbound NDUFV1 from the mitochondrial matrix.
Conversely, CAP decreased the mobility of NDUFS3-AcGFP1 and, to a lesser extent, NDUFB6-AcGFP1, sugges-
tive of their enrichment in less mobile subassemblies. Little, if any, change in mobility of NDUFA2-AcGFP1
could be detected, suggesting that the dynamics of this accessory subunit of the matrix arm remains unal-
tered. Finally, CAP increased the mobility of NDUFAF4–AcGFP1, indicative of interaction with a more mobile
membrane-bound subassembly. Our results show that the protein interactions of CI subunits and assembly
factors are differently altered when mitochondrial translation is defective.ﬂuorescent protein; BN-PAGE,
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Complex I (CI) is one of the ﬁve multi-subunit enzymes of the
mitochondrial oxidative phosphorylation (OXPHOS) system. The
enzyme exhibits several functions including the oxidation of NADH,
reduction of ubiquinone, conveyance of electrons released at the
site of NADH oxidation to the site of ubiquinone reduction and utili-
zation of part of their redox energy to transfer protons across the
mitochondrial inner membrane (MIM). As such, CI plays a crucialrole in the conversion of redox energy into the electrochemical
proton gradient used by complex V to synthesize ATP.
Human CI is built from 45 different proteins with an estimated
size of 1 MDa. The complex has an L-shaped structure with a peri-
pheral arm protruding in the matrix and a MIM-embedded mem-
brane arm. Functionally, CI can be divided into a dehydrogenase
module, which oxidizes NADH, a hydrogenase module, which trans-
fers the electrons and has been suggested to operate as a redox-driv-
en proton pump, and a transporter module, proposed to act as a
conformation-driven proton pump [15]. According to a hypothetical
scheme of the evolution of CI, the dehydrogenase module is thought
to consist of at least the NDUFV1, NDUFV2 and NDUFS1 subunits,
the hydrogenase module of at least the NDUFS2, NDUFS3, NDUFS7,
NDUFS8, ND1 and ND5 subunits and the transporter module of at
least the ND2, ND3, ND4, ND4L, and ND6 subunits [16]. The 7 ND sub-
units are encoded by the mitochondrial genome (mtDNA), whereas
the 7 NDUF subunits are encoded by the nuclear DNA (nDNA). In
mammals, the nDNA also encodes another 31 supernumerary or ac-
cessory subunits, whose function is only beginning to be understood.
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multi-step process, in which several subunits are ﬁrst combined
into smaller intermediates of the three functional modules. Subse-
quently, the holo-enzyme is formed by joining these preassembled
modules and additional subunits [2,11,22,27,40,41,44]. Parallel to
this de novo assembly route, an ‘exchange pathway’ was proposed,
in which newly imported subunits replace their previously incorpo-
rated counterparts in the holo enzyme. This mechanism might serve
to restore oxidatively damaged CI subunits [22]. Several non-structural
proteins have been identiﬁed to be required for proper assembly of
CI [1,7,12,13,23–25,30,31,34,39,42,43]. Recent blue native electropho-
resis work revealed that two of these assembly factors, NDUFAF3 and
NDUFAF4, are present in several NDUFS3-containing subcomplexes
[31]. It was proposed that NDUFAF4 forms a MIM-associated complex
with an early peripheral arm assembly intermediate and NDUFAF3
bound to themitochondrial assemblymachinery. In this way, NDUFAF3
assists in MIM insertion of newly formed ND subunits, thus allowing
their joining with the early CI assembly intermediate.
Together, these ﬁndings indicate that CI assembly is a highly dy-
namic process warranting detailed investigation in live cells. To this
end we stably expressed six AcGFP1-tagged CI subunits in HEK293
cells [11]. Using ﬂuorescence recovery after photobleaching (FRAP)
analysis, we provided evidence that each subunit was partially pre-
sent in holo CI. Four subunits (NDUFV1, NDUFV2, NDUFA2, and
NDUFA12) were also present as highly mobile matrix-soluble mono-
mers, whereas two other subunits (NDUFB6 and NDUFS3) were addi-
tionally present in a slowly mobile fraction. In the case of the integral
MIM protein NDUFB6, this fraction most likely represents one or
more membrane-bound subassemblies, whereas biochemical evi-
dence suggests that for the NDUFS3 protein this fraction might
correspond to a matrix-soluble subassembly [11].
Maintenance of cellular CI levels requires the biosynthesis of not
only its mtDNA- and nDNA-encoded structural subunits along with
its nDNA-encoded assembly factors but also of nDNA-encoded con-
stituents of the mitochondrial import machinery and nDNA-encoded
factors controlling the stability, replication, transcription and transla-
tion of the mtDNA [21]. Malfunction of CI can be caused by defects at
each of these levels as has been demonstrated in patients with isola-
ted or combined CI deﬁciency [36]. Defective mitochondrial transla-
tion leads to a marked reduction in CI expression [8,35]. However,
so far no live cell information is available on the effect of this condi-
tion on the dynamics of the CI assembly process. Therefore, we here
performed FRAP analysis on cells expressing the AcGFP1-tagged ver-
sions of the nDNA-encoded structural subunits NDUFV1, NDUFS3 and
NDUFB6, predicted to be part of the dehydrogenase, hydrogenase and
membrane module, respectively. In addition, we included accessory
subunit NDUFA2, located in the matrix-protruding arm of CI, and CI
assembly factor NDUFAF4. Mutations in both proteins have been
identiﬁed in patients with CI deﬁciency, demonstrating their essential
role in CI maintenance [20,31].
Our results reveal that CI structural proteins and assembly factors
display different live cell dynamics upon depletion of mtDNA-
encoded (ND) subunits, whichmay be indicative of the relative stabil-
ities of the corresponding functional modules and/or their
intermediates.
2. Materials and methods
2.1. Cell lines and cell culture
Cell lines expressing AcGFP1-tagged versions of NDUFV1, NDUFS3,
NDUFA2, NDUFB6 and NDUFAF4 and control cell lines expressing
matrix-targeted AcGFP1 (GFP), the matrix-targeted tandem version
of AcGFP1 (GFP2) and AcGFP1-tagged ANT1 were generated as de-
scribed previously [10,11]. Cells were cultured in DMEM (Biowhitaker,
Walkersville, MD, USA) supplemented with 10% (v/v) fetal calf serum,1% penicillin/streptomycin (Gibco, Breda, The Netherlands), 200 μg/ml
hygromycine (Calbiochem, Brunschwig, Amsterdam, The Netherlands)
and 50 μg/ml blasticidin (Invitrogen, Breda, The Netherlands). All cell
lines, except those expressing the tagged versions of NDUFB6, GFP2
andANT, displayed low steady-state expression levels already in the ab-
sence of doxycycline. Therefore, expression of NDUFB6, GFP2 and ANT
was induced by adding 1 μg/ml of doxycycline (Sigma, Zwijndrecht,
The Netherlands) to the medium during the last 24 h of culture.
Mitochondrial translationwas inhibited by adding 40 μg/ml of chloram-
phenicol (CAP; Sigma) to the medium for 3 days prior to harvesting of
the cells for PAGE analysis or FRAP imaging.
2.2. BN-PAGE and SDS-PAGE analysis
After harvesting of the cells, mitochondrial lysates were prepared
and run on native 5–15% gradient gels as described previously [6].
In-gel ﬂuorescence emission was scanned using an imaging analyzer
(FLA5000, Fujiﬁlm, Tilburg, The Netherlands) equippedwith a 473 nm
excitation laser and a FITC ﬁlter (N510 nm). Subsequently, duplo
gels were stained for CI in-gel activity as described in [6] or blotted
on nitrocellulose using an iBlot® Dry Blotting System (Invitrogen)
after 10 min incubationwith 2×Nu-PAGE transfer buffer (Invitrogen).
A separate fraction of mitochondrial lysate was denatured in Tricine
sample buffer (Biorad, Veenendaal, The Netherlands) and separated
on a 10% SDS-PAGE Tris-Tricine gel for scanning of in-gel ﬂuorescence
emission and blotting on nitrocellulose.
2.3. Antibodies and ECL detection
Immunostaining was performed using primary antibodies against
ND1 (a gift from Dr. A. Lombès, Inserm U975, Paris, France), the CII
70-kDa subunit (SDHA; Invitrogen) and EGFP (a gift from Dr. F.J. van
Kuppeveld,MedicalMicrobiology, RUNMC,Nijmegen, TheNetherlands)
in combination with horseradish peroxidase-conjugated secondary
antibodies (anti-rabbit or anti-mouse). Signals were detected by ECL
(Pierce, Rockford, USA).
2.4. FRAP analysis
Cells were grown to ~70% conﬂuence in a Wilco© dish (Intracel
Ltd., Royston, UK). Prior to imaging, culture medium was replaced
by a colorless HEPES–Tris (HT) solution (132 mM NaCl, 4.2 mM KCl,
1 mM CaCl2, 1 mM MgCl2, 5.5 mM D-glucose and 10 mM HEPES,
pH 7.4). FRAP recordings were performed on a ZEISS LSM510 Meta
confocal microscope (Carl Zeiss B.V., Sliedrecht, The Netherlands) at
a rate of 10 Hz using a ×63 oil immersion objective (N.A. 1.4; zoom
factor of 4; optical section thickness b2 μm) as described before
[11]. After selection of a mitochondrion of interest (average length
of 3 μm), pre-bleach images were collected at 488 nm light from an
argon-ion laser set at 0.1% transmission. Next, part of the mitochon-
drion, referred to as the FRAP region, was photobleached during
500 ms at 100% transmission. Post-bleach images were recorded at
0.1% transmission (Supplemental Fig. S1). The pre-bleach images
were used to calculate the initial ﬂuorescence intensity for a mito-
chondria-free region (Fi,background), the FRAP region (Fi,FRAPregion) and
the total mitochondrion (Fi,totalmito). The same was done for each
post-bleach image. Individual ﬂuorescence recovery curves (F(t)),
corrected for the loss of ﬂuorescence and expressed as a percentage
of the initial signal, were obtained using:
F tð Þ ¼ 100×
F tð Þ
FRAPregion
−F tð Þbackground
 
F tð Þtotalmito−F tð Þbackground
  ×
Fi;totalmito−Fi;background
 
Fi;FRAPregion−Fi;background
 
ð1Þ
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component exponential association model using Eq. (2).
F tð Þ ¼ y0 þ A1 1−e−t=tfast
 
þ A2 1−e−t=tslow
 
ð2Þ
Finally, the mobile fraction (Fm) was calculated according to:
Fm ¼
F∞−F0
Finitial−F0
ð3Þ
With Finitial being 100% by deﬁnition, F∞ being the ﬂuorescence
value at t∞ (calculated from Eq. (2)) and F0 being the ﬂuorescence
value immediately after the bleach pulse (Table 1). In order to test
whether induction of protein expression as such affected matrix pro-
tein diffusion, we compared the ﬂuorescence recovery between the
induced and non-induced GFP cell line. No differences in recovery
kinetics were observed (data not shown).
2.5. Image processing, curve ﬁtting and statistics
For image processing and analysis we used LSM 510 Meta soft-
ware (Zeiss) and Image Pro Plus 5.1 (Media Cybernetics, Bethesda,
MD, USA). Non-linear curve ﬁtting (using the Levenberg-Marquardt
algorithm) and statistical analysis was performed using Origin
Pro 7.5 (Originlabs, Northampton, MA, USA). Values from multiple
experiments are expressed as mean±SEM (standard error of the
mean).
3. Results
3.1. Assembly patterns of ﬂuorescently labeled CI structural and assembly
factor proteins after inhibition of mitochondrial translation
The effect of ND-subunit depletion on the assembly pattern of
several nDNA-encoded CI subunits and a recently discovered CITable 1
Fitting results of the FRAP curves obtained in different HEK293 cell lines in the absence
or presence of chloramphenicol (CAP).
Cell line aMW bN cR2 dtfast etslow fF0 gFm
GFP 27.9 38 0.991 0.326±0.079 1.30±0.206 11±1.7 0.96
GFP+CAP 27.9 21 0.991 0.390±0.140 1.93±0.228 9.1±2.0 0.94
GFP2 55.8 45 0.992 0.485±0.163 2.40±0.262 15±2.4 0.99
GFP2+CAP 55.8 35 0.998 0.550±0.097 5.22±0.819 10±1.2 0.94
ANT 62.8 116 0.988 0.129±0.025 8.37±0.441 21±1.2 0.63
ANT+CAP 62.8 53 0.984 0.382±0.084 6.68±0.462 17±1.3 0.59
NDUFV1 77.5 68 0.961 0.350±0.047 3.58±0.376 29±1.8 0.53
NDUFV1+CAP 77.5 26 0.931 0.272±0.055 1.91±0.259 22±3.6 0.73
NDUFS3 55.3 85 0.967 0.382±0.048 3.72±0.376 28±2.0 0.47
NDUFS3+CAP 55.3 29 0.954 0.632±0.089 14.2±5.22 22±3.0 0.73
NDUFA2 39.7 49 0.973 0.244±0.034 1.75±0.130 29±2.6 0.70
NDUFA2+CAP 39.7 31 0.980 0.481±0.076 2.54±0.231 21±2.1 0.81
NDUFB6 44.3 101 0.977 0.162±0.028 6.89±0.466 22±1.8 0.39
NDUFB6+CAP 44.3 45 0.962 0.259±0.061 8.81±0.960 12±1.6 0.49
NDUFAF4 50.1 50 0.989 0.569±0.080 10.7±1.12 6.8±1.0 0.54
NDUFAF4+CAP 50.1 45 0.989 0.650±0.178 7.38±0.619 10±1.5 0.54
In this table errors (±) represent standard error of the mean (SEM).
a Predicted MW of the protein (kDa), including size of linker (2 kDa) and AcGFP1
(27.9 kDa).
b Total number of mitochondria analyzed on at least 2 different days.
c Coefﬁcient of determination, being the proportion of variability in the average
FRAP curve that is accounted for by the ﬁt (calculated using Eq. (2)).
d Time constant of fast FRAP recovery phase in seconds (larger means slower).
e Time constant of slow FRAP recovery phase in seconds (larger means slower).
f Starting (minimal) level of ﬂuorescence recovery (% of pre-bleach level).
g Mobile fraction (calculated using Eq. (3)).assembly factor was investigated in inducible HEK293 cell lines
expressing AcGFP1-tagged versions of these proteins [11,31]. To ob-
tain information about the different functional modules of the com-
plex, we selected NDUFV1 and NDUFS3, predicted to be structural
subunits of the dehydrogenase and hydrogenase module, respec-
tively. In addition, we included NDUFA2 and NDUFB6, thought to
reside in the matrix-protruding and membrane arm, respectively,
and the CI assembly factor NDUFAF4. Four of the ﬁve cell lines
(NDUFV1, NDUFS3, NDUFA2, NDUFAF4) expressed the tagged subu-
nit under non-induced conditions (leakage) which minimized the
risks of overexpression artifacts. An additional advantage is that
under leakage conditions the incorporation of tagged proteins is
at steady state. Importantly, in previous work we showed that CI-
incorporation of AcGFP1-tagged NDUFV1, NDUFS3, NDUFA2, NDUFB6
and NDUFAF4 did not alter CI expression and activity, even when
their expression levels were high [10,11,31,41]. In line with these
ﬁndings, AcGFP1-tagged NDUFS3, NDUFA2, NDUFB6 and NDUFAF4
showed similar assembly patterns as their endogenous counterparts.
However, the best proof for their functionality was delivered by
AcGFP1-tagged NDUFA2 and NDUFAF4, which could complement
CI deﬁcient patient cells containing mutations in their endogenous
genes [20,31].
The assembly pattern of the ﬁve AcGFP1-tagged proteins was ana-
lyzed on native gels of mitochondrial fractions from cells cultured in
the absence (−) and presence (+) of the mitochondrial translation
blocker chloramphenicol (CAP; Fig. 1A). Labeled holo CI and its subas-
semblies were visualized by ﬂuorescence scanning of the gel (lanes
marked f) and immunostaining with an anti-EGFP antibody on a
Western blot of the same gel (lanes marked a). In the absence of
CAP, both detection methods revealed the presence of AcGFP1-tagged
subunit at the height of holo CI (closed arrow heads) for NDUFV1,
NDUFS3, NDUFA2. NDUFB6 showed a very dim smear around CI on
the ﬂuoroscan, whereas a more distinct band was observed on the
Western blot. No signal at the height of holo CI was visible for assem-
bly factor NDUFAF4. Using antibody detection, distinct bands of lower
MW, previously identiﬁed as CI assembly intermediates [31,41], were
demonstrated for NDUFS3 and NDUFAF4 (Fig. 1A, open arrowheads
1–6). As reported previously, an additional band just below CI
(open arrowhead 6′) was observed for NDUFAF4 [31]. For NDUFV1
and NDUFA2, also other (faint) bands of lower MW were seen,
whereas NDUFB6 showed a smear below CI, compatible with previ-
ous ﬁndings [11,40,41].
CAP-treatment greatly reduced the intensity of the signals at
the height of holo CI. For NDUFS3, this effect was accompanied by
an increase in subcomplexes 2 and 3, whereas subcomplexes 4, 5
and 6 were virtually absent. A similar result was obtained for NDU-
FAF4, where both the monomeric form and subcomplex 3 were mark-
edly increased and subcomplexes 4, 5, 6 and 6′ were only barely
detectable. CAP-treatment diminished the lower MW bands for
NDUFV1, NDUFA2 and NDUFB6.
Analysis of identical amounts of the same mitochondrial lysates
on SDS-PAGE gels revealed lowered expression levels upon CAP-
treatment for AcGFP1-tagged NDUFV1, NDUFA2 and NDUFB6,
whereas the total amount of AcGFP1-tagged NDUFS3 and NDUFAF4
were hardly altered (Fig. 1B). In addition to the intact fusion pro-
teins also smaller ﬂuorescent breakdown products were observed
for NDUFV1, NDUFS3 and NDUFA2. Importantly, the expression of
tagged subunits in leakage cells is extremely low (for NDUFS3 less
than 5% of the total amount of NDUFS3 [10,41]), which makes it un-
likely that these breakdown products originate from overexpression.
They might rather reﬂect unavoidable products of protein turnover.
Virtually no lower MW-bands were observed in induced NDUFB6–
AcGFP1 cells and leakage NDUFAF4–AcGFP1 cells.
Parallel analysis for CI in-gel activity and mtDNA-encoded ND1
abundance (Fig. 1C, IGA and ND1, respectively) demonstrated that
CAP effectively reduced both.
Fig. 1. Effect of CAP on the assembly proﬁle of AcGFP1-tagged CI subunits and assembly factor. Cell lines expressing AcGFP1-tagged NDUFV1, NDUFS3, NDUFA2, NDUFB6 and
assembly factor NDUFAF4 were cultured in the absence (−) or presence (+) of CAP for 3 days. Next, mitochondrial lysates were prepared and subjected to BN- and SDS-
PAGE in parallel. (A) Fluorograms of BN-PAGE gels (f) and Western blots of BN-PAGE gels stained with anti-EGFP (a). The position of holo CI is marked with closed arrowheads.
Open arrowheads indicate CI assembly intermediates 1–6 and 6′ and monomeric protein m. Asterisks indicate speciﬁc ﬂuorescent bands also detected in wild type cells (not
shown). (B) Fluorograms of SDS-PAGE gels of identical samples shown in A. Closed arrowheads indicate the intact fusion proteins at the expected molecular weight. Height
of MW-marker bands (25 and 75 kDa) are indicated by arrows. (C) CI in-gel activity (IGA) measurements on BN-PAGE gels and Western blots of BN-PAGE gels stained with
anti-SDHA (SDHA; loading control). Parallel SDS-PAGE Western blots of identical samples stained with anti-ND1 (ND1).
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increased after inhibition of mitochondrial translation
Next, we studied the effect of CAP on the mobility of the nDNA-
encoded CI structural subunits and assembly factor NDUFAF4. To
this end, we compared their sub-mitochondrial ﬂuorescence recovery
after photobleaching (FRAP) characteristics (Fig. 2A–E) in the absence
(closed symbols) and presence (open symbols) of CAP. Recovery ki-
netics were ﬁtted using a two-component model [11,28] (smooth
blue and red curves for (−) and (+) CAP conditions, respectively).
On average, the relative amount of mobile molecules (mobile frac-
tion; Fm) for cells cultured in the absence of CAP (Fig. 2F, blue bars
and Table 1) ranged between 0.39 (NDUFB6) and 0.70 (NDUFA2).
This indicates that a considerable fraction of tagged subunit (i.e.
61% for NDUFB6 and 30% for NDUFA2) was immobile in the pre-
sence of ND-subunits (Table 1). For all four subunits, CAP treat-
ment increased their Fm (Fig. 2F, red bars and Table 1). In
contrast, CAP did not alter the Fm for NDUFAF4, indicating that its
effect on the Fm for CI structural subunits was not due to non-spe-
ciﬁc effects on protein diffusion in the mitochondrial matrix and/or
MIM. To substantiate this conclusion, we analyzed the effect of CAP
in three ‘control’ HEK293 cell lines, conditionally expressing either
a mitochondrial matrix-targeted AcGFP1 (cell line designated
‘GFP’), a mitochondrial matrix-targeted tandem fusion of AcGFP1
(cell line designated ‘GFP2’), or an N-terminal fusion of AcGFP1 to
the integral MIM-protein adenine nucleotide translocase 1 (cell
line designated ‘ANT’). Proper expression of these fusion proteins
was demonstrated by SDS-PAGE (Fig. 3A). Fluorescence scanning
(lanes indicated f) and anti-EGFP immunostaining (lanes indicated
a) revealed speciﬁc bands of the expected size in both the absence
(−) and presence (+) of CAP. The effectiveness of CAP was de-
monstrated by the reduction in CI in-gel activity (Fig. 3B, panels in-
dicated IGA) and ND1 expression (Fig. 3C). Recovery curves of GFP,
GFP2 and ANT cells (Fig. 3D–F), determined in the absence (closed
symbols, blue curves) and presence (open symbols, red curves) of
CAP, show that blocking mitochondrial translation hardly affectedFm (Table 1 and Fig. 3G). This supports the above conclusion that
ND-subunit depletion speciﬁcally increased the mobile fraction of
the investigated CI structural subunits.
3.3. The recovery kinetics of ﬂuorescently labeled CI structural subunits is
differently altered after inhibition of mitochondrial translation
To further explore the changes in mobility of nDNA-encoded CI
subunits upon inhibition of mitochondrial translation we quantiﬁed
the FRAP kinetics of the mobile proteins. Fitting of the FRAP curves
using a two-component model yielded two time constants (Table 1).
We previously demonstrated that the rate of the initial fast recovery
phase (i.e. tfast) is less informative since it might be affected by small
amounts of ﬂuorescent breakdownproducts [11]. This is substantiated
by the fact that the fast component of the FRAP-signal was virtually
absent in cells without breakdown products (NDUFB6, NDUFAF4 and
ANT cells), reﬂected by the limited amount of data points constituting
their fast phase of the recovery curve (Fig. 2D, E and Fig. 3F). Therefore,
we focus on the slower recovery phase (i.e. tslow). Data concerning tfast
is presented in Table 1.
Proper comparison of tslow between the different proteins re-
quires that the size of the individual proteins is taken into account
[9,11,38]. Therefore, we plotted the tslow values against the mole-
cular weight (MW) of the studied proteins (Fig. 4A, B). To establish
this relationship for unconjugated matrix diffusing proteins, a li-
near ﬁt was calculated through the origin and the coordinates of
GFP and GFP2 (blue and red lines, respectively). Any tslow value
above these lines (e.g. ANT) indicates that ﬂuorescence recovery
is slower than expected on the basis of the MW of the protein.
This means that the protein is binding to other matrix- or MIM-
proteins or to the MIM itself. Here, it should be noted that CAP in-
creased the tslow values of GFP and GFP2, whereas it decreased that
of ANT. One possible explanation is that CAP alters the ultrastruc-
ture and/or density of the mitochondrial matrix as was demon-
strated in persons that received CAP-therapy [37]. The underlying
cause could be CAP-induced misassembly of F1/F0-ATPsynthase
Fig. 2. Effect of CAP on the FRAP kinetics of AcGFP1-tagged CI subunits and assembly factor. Averaged FRAP curves (open and closed symbols) and two-component model ﬁts (blue
and red lines) of cell lines cultured in absence (closed symbols, blue lines) or presence (open symbols, red lines) of CAP for 3 days prior to FRAP imaging. (A) NDUFV1, (B) NDUFS3,
(C) NDUFA2, (D) NDUFB6 and (E) NDUFAF4. (F) Relative size of the mobile fraction (Fm) in the different cell lines following culturing in the absence (blue bars) or presence (red
bars) of CAP. Mobility values are given in Table 1.
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taining cristae morphology [3,18,26]. Recently we have shown that
protein diffusion in the mitochondrial matrix is greatly hindered
by cristae [9]. We here observed that the number of cristae in
CAP-treated cells was reduced when compared to non-treated
cells (see Supplemental Fig. S2B/C). This suggests that the slowing
effect of CAP on the ﬂuorescence recovery signals of GFP and GFP2
is not due to an increase in the number of cristae. This leaves open
the possibility that mitochondrial matrix viscosity is increased in
CAP-treated cells.
In the absence of CAP (Fig. 4A), the tslow values for NDUFA2 and
NDUFV1 were located on the line, indicating that they were not
bound. On the other hand, those for NDUFS3, NDUFB6 and NDUFAF4
were above this line, suggesting slower diffusion due to protein and/
or membrane interactions [11]. In CAP-treated cells, we observed an
increase in tslow for both GFP and GFP2 (Fig. 4B and Table 1). Ne-
vertheless, the relationship between tslow and MW for these proteinsremained linear. Increased tslow values were also observed for
NDUFA2, which remained virtually on the line, NDUFB6, for which
the effect was relatively small, and NDUFS3, which showed a large
decrease in mobility. On the other hand, CAP-treatment decreased
tslow for ANT, NDUFAF4 and NDUFV1. In the case of NDUFV1, the
tslow value was clearly located below the line. In fact, this value
was similar to that of GFP, suggesting that the mobile fraction repre-
sented AcGFP1 rather than AcGFP1-tagged NDUFV1.
In summary, defective mitochondrial translation increased the
mobile fraction of all four nDNA-encoded subunits investigated. How-
ever, its effect on the mobility of these subunits was large and oppo-
site for NDUFV1 (located in the dehydrogenase module) and NDUFS3
(located in the hydrogenase module), relatively small for NDUFB6
(located in the membrane module) and virtually absent for NDUFA2
(of so far undeﬁned localization). Regarding NDUFAF4 (a CI assembly
factor), CAP-induced ND-subunit depletion did not alter the mobile
fraction, while it increased its mobility.
Fig. 3. Effect of CAP on the FRAP kinetics of matrix-soluble and MIM-bound proteins. Cell lines expressing either matrix-targeted AcGFP1 (GFP), matrix-targeted tandem version
of AcGFP1 (GFP2) or ANT1-linked AcGFP1 (ANT) were cultured in absence (−) or presence (+) of CAP and processed for BN- and SDS-PAGE as described in the legend to Fig. 1.
(A) Fluorograms of SDS-PAGE gels (f) and Western blots of SDS-PAGE gels stained with anti-EGFP (a). (B) CI in-gel activity (IGA) measurements on BN-PAGE gels and anti-
SDHA Western blots of BN-PAGE gels (SDHA; loading control). (C) Anti-ND1 Western blots of SDS-PAGE gels (ND1). (D–G) Averaged FRAP curves (open and closed symbols)
and two-component model ﬁts (blue and red lines) of cell lines cultured in absence (closed symbols, blue lines) or presence (open symbols, red lines) of CAP. (G) Relative size
of the mobile fraction (Fm) in the different cell lines following culturing in the absence (blue bars) or presence (red bars) of CAP. Mobility values are given in Table 1.
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The present study uses FRAP analysis to obtain live cell informa-
tion about the role of mitochondrial translation in the dynamics of in-
dividual CI subunits and their functional CI modules. The strategy
chosen was to compare the live cell FRAP characteristics of AcGFP1-tagged versions of CI subunits and a CI assembly factor in the absence
and presence of the mitochondrial translation inhibitor chloram-
phenicol (CAP). The effectiveness of the CAP-treatment was con-
ﬁrmed by blue native analysis of mitochondrial lysates, showing
a marked decrease in the amount of holo CI but not its complete dis-
appearance. Consistent with this ﬁnding, FRAP analysis revealed that
Fig. 4. Effect of CAP on the mobility of the fusion protein as a function of its molecular weight. The kinetics of the recovery phase of the mobile fraction was quantiﬁed by ﬁtting to a
two-component model, yielding a tfast and a tslow. Because previous work revealed that tfast was little informative [11] we here focus on tslow. (A) Plot of average tslow (mean±SEM)
versusMW in untreated cells. As reported before [11], the values for GFP and GFP2 are on a line through the origin (blue line). (B) Plot of average tslow (mean±SEM) versusMW in
CAP-treated cells. The values for GFP and GFP2 are on a line through the origin (red line). The obtained R values of the ﬁt are 1±0.09 (−CAP) and 1±0.61 (+CAP).
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tagged CI subunits but did not nullify this fraction. The parallel de-
crease in amount of holo CI and relative size of the immobile fraction,
strongly suggests that in the living cell the mobility of the holo com-
plex is very low. This is in agreement with the idea that CI constitutes
part of respiratory supercomplexes [4,33,45] and the observation that
ﬂuorescently labeled CI shows localized (immobile) patches that do
not redistribute over mitochondrial ﬁlaments by mitochondrial fu-
sion and ﬁssion [5].
4.1. Dynamics of NDUFV1 and the dehydrogenase module
Under normal conditions, 53% of NDUFV1–AcGFP1 is present in
the mobile fraction. Our data show that this fraction consists entirely
of monomeric NDUFV1–AcGFP1. This conclusion is based on the fact
that the mobility of this fraction is exactly as predicted on the basis
of its molecular weight. Regarding the GFP-positive subcomplex
seen on a BN-gel, this means that it is most probably a MIM-bound
intermediate. One important implication of our ﬁndings is that
under normal conditions the dehydrogenase module exists, if at all,
in the membrane-bound form. This strongly suggests that the dehy-
drogenase module is assembled in a subunit-by-subunit manner on
top of a MIM-bound CI intermediate. Keeping this in mind, the pic-
ture emerges that the dehydrogenase module is a highly dynamic
part of CI that is assembled and disassembled depending on cellular
needs. In this context, it would be of interest to assess the effect of
changes in metabolic state on the size of the mobile fraction of
NDUFV1–AcGFP1.
Intriguingly, CAP-treatment signiﬁcantly increased the mobility
of the mobile fraction of NDUFV1–AcGFP1 to the same value as ob-
served with AcGFP1 alone. This result clearly demonstrates that in
CAP-treated cells, in sharp contrast to untreated cells, virtually all
unbound NDUFV1–AcGFP1 is removed from the mitochondrial ma-
trix. In other words, this means that either all NDUFV1–AcGFP1
that is left in the mitochondrial matrix is broken down or bound
to an immobile (sub)complex. The fact that CAP-treatment does
not exert the same effect on the tandem fusion of AcGFP1 strongly
suggests that NDUFV1 itself is degraded by a mechanism that leaves
its fusion partner AcGFP1 intact. How to explain the decreased
amount of unbound NDUFV1–AcGFP1 in the mitochondrial matrix?
A possible explanation is that under normal conditions CI-bound
NDUFV1 is continuously exchanged for unbound NDUFV1, possibly
protecting this subunit from being captured by the machinery that
causes its degradation. In vitro evidence for such an exchange mech-
anism has been provided recently [22]. This explanation would be
compatible with the above idea of a subunit-by-subunit assemblyof the dehydrogenase module on top of a MIM-bound CI intermedi-
ate. Maintenance of this putative intermediate would then require
the continuous formation of mtDNA-encoded (ND) subunits so that
it will gradually disappear upon inhibition of mitochondrial transla-
tion. An alternative explanation is that CAP-treatment might lead to
the activation of processes that degrade unbound subunits such as
NDUFV1. One possibility might be the increased production of su-
peroxide, which was found to occur (unpublished data) in cultured
skin ﬁbroblasts of a patient with a mutation in the mitochondrial
translation elongation factor EFTs [35]. Since NDUFV1 contains the
NADH binding site, FMN and the N3 iron sulfur cluster [14,19,32],
the possibility exists that it takes up electrons and converts these
into superoxide and its derived reactive oxygen species (ROS), fac-
tors that may contribute to its instability. Moreover, the presence
of an iron sulfur cluster may increase its susceptibility for ROS pro-
duced by the Fenton reaction.
4.2. Dynamics of NDUFA2, a hitherto undeﬁned peripheral arm subunit
The NDUFA2 subunit is a paralogue of the mitochondrial ribo-
somal proteins L43 and S25, suggesting that it may play a role in
mitochondrial translation [17]. Under normal conditions, 70% of
NDUFA2–AcGFP1 is present in the unbound form. In this respect,
NDUFA2 behaves similar to NDUFV1. CAP-treatment increased its
mobile fraction to 81% but, unfortunately, tslow vs. molecular
weight analysis did not allow drawing any ﬁrm conclusion regard-
ing the effect of this treatment on the intactness of the fusion pro-
tein. Most probably, part of it is present in the intact form, whereas the
remainder is degraded to AcGFP1. Because mutations in NDUFA2 lead
to CI deﬁciency [20], paralleled by a marked decrease in the amount
of holo CI, this subunit likely plays a crucial role in CI maintenance
and/or stabilization.Why such a role is accompanied with the presence
of excess unbound subunit is presently unclear. As for NDUFV1, we
speculate that NDUFA2 is involved in the regulation of CI activity
through the control of its assembly status.
4.3. Dynamics of NDUFS3 and the hydrogenase module
Under normal conditions, about 50% of NDUFS3–AcGFP1 is pre-
sent in the immobile fraction proposed before to consist of holo CI
and several MIM-bound subcomplexes [11]. The remainder is pre-
sent in a mobile fraction characterized by a relatively slow mobility.
Previous work suggested that this latter fraction likely comprises a
matrix-soluble assembly of ~100 kDa consisting of NDUFS3–AcGFP1
and several associated proteins [11]. The present study shows that
CAP-treatment increased the size of the mobile fraction and, at the
Fig. 5. Schematic presentation of CI assembly (A) under normal conditions and (B) after
inhibition of mitochondrial translation (see Discussion for details).
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that NDUFS3–AcGFP1, in sharp contrast to NDUFV1–AcGFP1, is pre-
served in relatively slowly mobile subcomplexes. Another important
ﬁnding is that CAP-treatment did not result in the formation of new
CI subcomplex species but rather changed the relative amounts of al-
ready existing subcomplexes as was revealed by blue native gel ana-
lysis. In more detail, the latter technique revealed that CAP-
treatment decreased the amount of holo CI and its subcomplexes 4,
5, 6 and, to a lesser extent, 1, whereas it increased the amount of sub-
complexes 2 and 3 (see also [31,41]). Previous work suggested that
subcomplex 1 is matrix-soluble, whereas subcomplexes 2 and 3 are
relatively loosely membrane-bound and subcomplexes 4, 5 and 6 are
relatively tightly membrane-bound [11]. Taken together, these and
the present ﬁndings indicate that the CAP-induced increase of themo-
bile fraction of NDUFS3–AcGFP1 reﬂects the disappearance of holo CI
and its subcomplexes 4, 5 and 6, whereas the CAP-induced decrease
in mobility of this fraction reﬂects the decrease in soluble subcomplex
1 and the increase in subcomplexes 2 and 3. This, then, indicates that
the latter two complexes are slowly mobile. According to the present
concept of CI assembly, these latter two subcomplexes might provide
a scaffold for the coordinated translation and incorporation of ND-
subunits assisted by CI assembly factors NDUFAF3 and NDUFAF4
[31]. After CAP treatment, NDUFAF4 exists as a MIM-bound monomer
and is part of subcomplex 3, but not of subcomplex 2 (also see discus-
sion below). The tslow of NDUFAF4 after CAP treatment is smaller than
the respective tslow of NDUFS3. Given the fact that tslow in NDUFS3 cells
reﬂects the mobility and kinetics of a mixed population of assemblies,
matrix-soluble monomers and possibly breakdown products, these
NDUFAF4 data strongly suggest that subcomplex 2 ismuch lessmobile
than subcomplex 3. NDUFS3 is considered to be part of the hydroge-
nasemodule and the present data suggest that thismodule, in contrast
to the dehydrogenase module, is relatively stable in the absence of
mtDNA-encoded subunits. Similar conclusions regarding the stability
of CI subunits were drawn from in vitro analysis of cells lacking mito-
chondrial DNA or in which mitochondrial translation was blocked,
showing that the amount of some subunits was dramatically de-
creased, whereas other subunits remained readily detectable
[3,29,40,46].
4.4. Dynamics of NDUFB6, a component of the membrane arm
On a blue native gel, endogenous and AcGFP1-tagged NDUFB6
yields a smear that spreads from holo CI to relatively small subcom-
plexes [11,40,41]. NDUFB6 is an integral membrane protein, so the
most likely explanation for this observation is that it forms an early
component in the subunit-by-subunit assembly of a relatively large
module, probably the membrane arm of the holo complex. Under
normal conditions a relatively large part of NDUFB6–AcGFP1 (61%)
is present in the immobile fraction, suggesting that the vast majority
of subcomplexes is virtually immobile. The remainder displays a rel-
atively slow mobility, which likely reﬂects its composition of a mix-
ture of more or less mobile MIM-bound intermediates. Upon CAP-
treatment, both the relative size of the immobile fraction and the
mobility of the mobile fraction slightly decreased, suggesting that
NDUFB6–AcGFP1 containing subcomplexes are relatively inert to in-
hibition of mitochondrial translation. This, then, means that these
subcomplexes predominantly consist of nDNA-encoded subunits,
which is in line with our model in which NDUFB6 subcomplexes
join with mtDNA-encoded subunits in a relatively late stage of as-
sembly to form the mature membrane arm of the complex [41].
4.5. Dynamics of the assembly factor NDUFAF4
Based on blue native analysis, the CI assembly factor NDUFAF4 has
been proposed to link an early assembly intermediate with the MIM
for subsequent joining of mtDNA-encoded subunits [31]. Undernormal conditions, 46% of NDUFAF4–AcGFP1 is present in the immo-
bile fraction, whereas the remainder is present in a mobile fraction
of which the mobility was slower than expected on the basis of the
molecular weight of the fusion protein. CAP-treatment did not alter
the size of the immobile fraction, whereas it increased the mobility
of the mobile fraction. Blue native gel analysis revealed that these
effects of CAP were paralleled by the virtual disappearance of the
subcomplexes 4, 5, 6 and 6′ and the increase in subcomplex 3 and
the monomeric form of the fusion protein. Based on previous work
showing that subcomplexes 4, 5 and 6 are relatively tightly mem-
brane-bound [11] and the conclusion of this study that subcomplex
3 is slowly mobile, these changes very well explain the relative in-
crease in mobility of the mobile fraction. The mobility of AcGFP1-
NDUFAF4 is signiﬁcantly lower than that of ANT in both the absence
and presence of CAP. Most probably the (sub)complexes that contain
NDUFAF4 are larger, and/or more restricted in diffusion by MIM-
microdomains. Together, these results are compatible with NDU-
FAF4 binding to a slowly mobile subcomplex 3 that lacks mtDNA-
encoded subunits but does contain NDUFS3 after which it remains
associated with the growing complex until shortly before comple-
tion of the holo complex. This last step appears to involve, probably
among others, the binding of NDUFV1 and NDUFA2, which were
not detected in the NDUFS3/NDUFAF4 containing subcomplexes.
Fig. 5 depicts our current model of CI assembly. In this model it
is assumed that assembly starts with NDUFS3 and a few other
nDNA-encoded subunits that form subcomplexes of the hydrogenase
module, of which subcomplex 3 is an important one since it binds
NDUFAF4 [31]. This binding of NDUFAF4 turns subcomplex 3 into a
proper scaffold for incorporation of mtDNA-encoded (ND) subunits
[31]. Subsequent fusion of other preassembled subcomplexes and
subunits results eventually in a mature CI. CAP-treatment preserves
NDUFS3 in subcomplexes 2 and 3, where it is protected against
1632 C.E.J. Dieteren et al. / Biochimica et Biophysica Acta 1807 (2011) 1624–1633degradation. The latter is not the case for NDUFV1 which is removed
from the mitochondrial matrix by either increased breakdown
(which might also be the case for NDUFA2), or binding to immobile
subcomplexes (indicated X).
In conclusion, our FRAP approach provided the ﬁrst explorative
data of CI subunit dynamics under normal and disturbed assembly
conditions in living cells. In the near future this could serve as a
new tool to obtain insight into CI assembly defects in live patients
cells.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbabio.2011.09.013.
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